35 results
8-K
MIRM
Mirum Pharmaceuticals Inc
16 Jan 24
Departure of Directors or Certain Officers
4:15pm
Blood Therapeutics, Inc. from November 2014 through April 2020, including as vice president, program leadership and business strategy, senior vice … for the company’s technical operations, supply chain, program management and leadership, quality assurance and commercial strategy and analytics functions. From
8-K
EX-99.1
MIRM
Mirum Pharmaceuticals Inc
5 Sep 23
Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics
8:36am
to $235 million in potential sales-based milestone payments
Expands Mirum’s leadership in rare liver disease with two additional commercial products
8-K
EX-99.1
gbxpr ji3s8xax9h
3 Aug 23
Results of Operations and Financial Condition
4:05pm
8-K
EX-99.1
eu5doivwh9wzym 0pd
17 Jul 23
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
8:16am
8-K
EX-99.2
ogr603o2
17 Jul 23
Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics
8:16am
8-K
EX-99.1
cgxo1
4 May 23
Results of Operations and Financial Condition
4:02pm
8-K
EX-99.1
bhu37v7rofs37x5lkko
6 Jun 22
Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors
8:32am
8-K
EX-99.2
7rf7ec2b23v7tdxnrcw
11 Jan 22
Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones
9:00am
8-K
EX-99.1
fg7fdrv
20 Aug 21
Mirum Pharmaceuticals Appoints Biotechnology Executive William C. Fairey to its Board of Directors
12:00am
DEF 14A
py8u0i
29 Apr 20
Definitive proxy
4:15pm
10-K
81fvd e9dpm9q2d
12 Mar 20
Annual report
4:16pm
8-K
EX-99.1
yjr0lzmpbp m2xihpgg
14 Jan 20
Departure of Directors or Certain Officers
4:00pm